Study wrapper · #811
GLP-1 receptor agonist adjunct therapy stabilises Ramadan dysglycaemia in insulin-treated diabetes: a CGM-based study.
Editor's note
A small, focused observational study with a genuinely peptide-specific question: whether adding semaglutide (a GLP-1 receptor agonist) or tirzepatide (a GLP-1/GIP dual agonist) to insulin helps stabilize blood sugar during Ramadan fasting. Using continuous glucose monitoring, researchers compared matched groups of insulin-treated type 2 diabetes patients with and without the add-on peptides. The reported signal is sizeable — time in range 74.4% versus 36.8%, and roughly a 61% reduction in the post-iftar glucose excursion — with no increase in hypoglycemia and no discontinuations. Two important caveats temper the finding: the study is small (18 per arm, 54 total) and observational rather than randomized, so matching on age, HbA1c and BMI cannot fully rule out confounding, and it collapses two distinct drugs into one 'add-on' arm, so we cannot separate semaglutide's contribution from tirzepatide's. The finding is promising and mechanistically coherent, but the evidence weight is modest.
Plain-language abstract
People with diabetes who take insulin face bigger blood-sugar swings during Ramadan, when eating patterns shift to nighttime. This study looked at whether adding a GLP-1-type medication — semaglutide or tirzepatide — on top of insulin helps steady blood sugar during the fast. Researchers used continuous glucose monitors on 54 adults across three groups: type 2 diabetes on insulin alone, type 2 diabetes on insulin plus one of the added drugs, and type 1 diabetes on insulin. They tracked glucose for about a month before and during Ramadan 2025. The group taking the added medication spent far more time in a healthy blood-sugar range (about 74% versus 37%) and had a roughly 61% smaller spike after the evening meal that breaks the fast. Importantly, this happened without more episodes of dangerously low blood sugar, and no one stopped treatment. The study is small and did not randomly assign people to treatments, and it combined the two drugs into one group, so it cannot say which drug drove the benefit or fully rule out other explanations.